Inovio Pharmaceuticals Inc (INO) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. INO reported $-0.35 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.33. The company posted revenue of $8.50 million in the period, compared to analysts expectations of $5.21 million. INO’s revenue was up 44.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.
Based on several research reports , Inovio Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Mar 16, 2017. Maxim Group Upgraded Inovio Pharmaceuticals Inc on Mar 16, 2017 to ” Buy”, Price Target of the shares are set at $10.
Several company insiders have filed Insider transactions , on Aug 30, 2016, Niranjan Sardesai (Chief Operating Officer) sold 21,800 shares at $9.30 per share price. According to the SEC, on Jun 29, 2016, Morton Collins (director) purchased 10,000 shares at $9.13 per share price. On May 18, 2016, Simon X Benito (director) sold 6,250 shares at $10.37 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovio Pharmaceuticals Inc opened for trading at $6.61 and hit $6.88 on the upside on Wednesday, eventually ending the session at $6.87, with a gain of 3.93% or 0.26 points. The heightened volatility saw the trading volume jump to 7,75,778 shares. Company has a market cap of $509 M.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.